Revised forecast
Fiscal year ending March 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Although sales of prismatic lithium-ion batteries whose production had ended and semiconductor-related products declined, net sales increased due to higher sales of primary batteries for medical equipment and infrastructure applications, as well as increased licensing revenue. Operating income increased despite higher raw material costs for primary batteries and increased development expenses for all-solid-state batteries, owing to improved profitability of prismatic lithium-ion batteries and increased licensing revenue. Ordinary income and net income declined mainly because dividends received from consolidated subsidiaries decreased.
| Item | Details |
|---|---|
| Net Sales | ¥72,414 million → ¥74,373 million（+2.7%） |
| Operating profit | ¥4,744 million → ¥5,608 million（+18.2%） |
| Ordinary income | ¥10,038 million → ¥7,069 million（-29.6%） |
| Profit attributable to owners of the parent | ¥8,323 million → ¥5,813 million（-30.2%） |
| Net income per share | 189.49 yen and sen → 142.17 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended March 2025 results (A): Net sales ¥72,414 million, operating income ¥4,744 million, ordinary income ¥10,038 million, net income ¥8,323 million, net income per share ¥189.49 |
| Reason for the revision | Although sales of prismatic lithium-ion batteries whose production had ended and semiconductor-related products declined, net sales increased due to higher sales of primary batteries for medical equipment and infrastructure applications, as well as increased licensing revenue. Operating income increased despite higher raw material costs for primary batteries and increased development expenses for all-solid-state batteries, owing to improved profitability of prismatic lithium-ion batteries and increased licensing revenue. Ordinary income and net income declined mainly because dividends received from consolidated subsidiaries decreased. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales and operating income increased due to higher sales of primary batteries for medical equipment and infrastructure applications, as well as increased licensing revenue. Ordinary income and net income declined mainly because dividends received from consolidated subsidiaries decreased.